Hematogen Forte

Ferrous Fumarate, Ascorbic Acid, Folic Acid, Cyanocobalamin


Nnodum Pharmaceuticals
Human Prescription Drug
NDC 63044-633
Hematogen Forte also known as Ferrous Fumarate, Ascorbic Acid, Folic Acid, Cyanocobalamin is a human prescription drug labeled by 'Nnodum Pharmaceuticals'. National Drug Code (NDC) number for Hematogen Forte is 63044-633. This drug is available in dosage form of Capsule, Gelatin Coated. The names of the active, medicinal ingredients in Hematogen Forte drug includes Ascorbic Acid - 1 mg/1 Cyanocobalamin - 10 mg/1 Ferrous Fumarate - 151 mg/1 Folic Acid - 10 mg/1 . The currest status of Hematogen Forte drug is Active.

Drug Information:

Drug NDC: 63044-633
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Hematogen Forte
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Ferrous Fumarate, Ascorbic Acid, Folic Acid, Cyanocobalamin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Nnodum Pharmaceuticals
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule, Gelatin Coated
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ASCORBIC ACID - 1 mg/1
CYANOCOBALAMIN - 10 mg/1
FERROUS FUMARATE - 151 mg/1
FOLIC ACID - 10 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 10 May, 2007
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Nnodum Pharmaceuticals
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000193618
M0001797
M0022794
N0000175951
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:PQ6CK8PD0R
P6YC3EG204
R5L488RY0Q
935E97BOY8
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Vitamin C [EPC]
Vitamin B12 [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Ascorbic Acid [CS]
Vitamin B 12 [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Ascorbic Acid [CS]
Vitamin B 12 [CS]
Vitamin B12 [EPC]
Vitamin C [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63044-633-2110 BLISTER PACK in 1 BOX (63044-633-21) / 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK10 May, 2007N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Hematogen forte ferrous fumarate, ascorbic acid, folic acid, cyanocobalamin ferrous fumarate ferrous cation soybean oil lecithin, soybean glycerin hydrogenated soybean oil titanium dioxide ascorbic acid ascorbic acid folic acid folic acid cyanocobalamin cyanocobalamin ziks;633

Boxed Warning:

Warning warning : accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. keep this product out of reach of children. in case of accidental overdose, call a doctor or poison control center immediately.

Indications and Usage:

Indications and usage for the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence.

Dosage and Administration:

Dosage and administration usual adult dose is 1-2 soft gelatin capsules daily, or as directed by a physician.

Contraindications:

Contraindications hemochromatosis and hemosiderosis are contraindications to iron therapy. folic acid is contraindicated in patients with pernicious anemia ( see precautions ). soybean oil, lecithin, di calcium phosphate anhydrous, beeswax yellow, hydrogenated soybean oil.

Adverse Reactions:

Adverse reactions average capsule doses in sensitive individuals or excessive dosage may cause nausea, skin rash, vomiting, diarrhea, precordial pain, or flushing of the face and extremities.

Pediatric Use:

Pediatric use safety and effectiveness in pediatric patients has not been established.

Geriatric Use:

Geriatric use clinical studies on this product have not been performed in sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of noncomitant

Description:

Description each brown soft gelatin capsule contains: ferrous fumarate............................................................................ 460 mg (151 mg elemental iron) ascorbic acid.................................................................................... 60 mg folic acid............................................................................................ 1 mg cyanocobalamin.............................................................................10 mcg the amount of elemental iron and the absorption of the iron components of commercial iron preparations vary widely. it is further established that certain "accessory components" may be included to enhance absorption and utilization of iron. hematogen forte capsules are formulated to provide the essential factors for a complete, versatile hematinic. inactive ingredients : soybean oil, lecithin, glycerin, hydrogenated soybean oil, yellow beewax, titanium oxide.

How Supplied:

How supplied each brown soft gelatin capsule is imprinted with “ziks633” on one side. ndc 63044-0633-21, 10 x 10, unit dose packs, in packs of 100’s. store at controlled room temperature 15°- 30°c (59°- 86°f). avoid excessive heat 40°c (104°f). avoid freezing.

Package Label Principal Display Panel:

Package label.principal display panel nnodum hematogenforte633label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.